Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...

Compounded tirzepatide isn’t FDA-approved. This means there’s no guarantee it’s safe or effective. If you’re considering it, go to a safe source. Just because you can buy tirzepatide ...

Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from ...

Growth stocks are equity shares likely to outperform their peers and the broader market. Here's a list of stocks that contain investment potential to beef up your portfolio.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

As the New Year begins, the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) is urging the public to avoid ...

Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Fractyl Health, Inc. (GUTS – Research Report). The associated price ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a "buy" rating for long-term investors despite current valuation metrics.

Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...